Incidence of second neoplasm in childhood cancer survivors treated with GH

An analysis of GeNeSIS and HypoCCS

Whitney W. Woodmansee, Alan G. Zimmermann, Christopher J. Child, Qi Rong, Eva Marie Erfurth, Paolo Beck-Peccoz, Werner F. Blum, Leslie L. Robison

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Objective: Childhood cancer survivors are commonly treated with GH for GH deficiency that develops either as a result of primary malignancy or its treatment. One study - the Childhood Cancer Survivor Study (CCSS) - demonstrated increased risk of second neoplasm (SN) in GH-treated childhood cancer survivors compared with non-GH treated, after adjusting for key risk factors.We assessed the incidence of SN in GH-treated childhood cancer survivors in outpatient observational studies of GH replacement. Design: Retrospective analysis of two prospective cohort studies that collected data on safety of GH replacement as prescribed in clinical practice. Methods: Childhood cancer survivors enrolled in Eli Lilly and Company's pediatric (Genetics and Neuroendocrinology of Short Stature International Study (GeNeSIS)) and adult (Hypopituitary Control and Complications Study (HypoCCS)) observational studies of GH treatment were assessed for incidence of SN. Results: The percentage of childhood cancer survivors treated with GH who developed a SN was 3.8% in pediatric GeNeSIS participants and 6.0% in adult HypoCCS participants. The estimated cumulative incidence of SN at 5 years of follow-up in these studies was 6.2 and 4.8% respectively. Conclusions: The incidence of SN in GeNeSIS and HypoCCS GH-treated participants is similar to the published literature and is thus consistent with increased risk of SN in childhood cancer survivors treated with GH. As follow-up times were relatively short (

Original languageEnglish
Pages (from-to)565-573
Number of pages9
JournalEuropean Journal of Endocrinology
Volume168
Issue number4
DOIs
Publication statusPublished - Apr 2013

Fingerprint

Neuroendocrinology
Second Primary Neoplasms
Incidence
Neoplasms
Observational Studies
Pediatrics
Cohort Studies
Outpatients
Prospective Studies
Safety

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Woodmansee, W. W., Zimmermann, A. G., Child, C. J., Rong, Q., Erfurth, E. M., Beck-Peccoz, P., ... Robison, L. L. (2013). Incidence of second neoplasm in childhood cancer survivors treated with GH: An analysis of GeNeSIS and HypoCCS. European Journal of Endocrinology, 168(4), 565-573. https://doi.org/10.1530/EJE-12-0967

Incidence of second neoplasm in childhood cancer survivors treated with GH : An analysis of GeNeSIS and HypoCCS. / Woodmansee, Whitney W.; Zimmermann, Alan G.; Child, Christopher J.; Rong, Qi; Erfurth, Eva Marie; Beck-Peccoz, Paolo; Blum, Werner F.; Robison, Leslie L.

In: European Journal of Endocrinology, Vol. 168, No. 4, 04.2013, p. 565-573.

Research output: Contribution to journalArticle

Woodmansee, WW, Zimmermann, AG, Child, CJ, Rong, Q, Erfurth, EM, Beck-Peccoz, P, Blum, WF & Robison, LL 2013, 'Incidence of second neoplasm in childhood cancer survivors treated with GH: An analysis of GeNeSIS and HypoCCS', European Journal of Endocrinology, vol. 168, no. 4, pp. 565-573. https://doi.org/10.1530/EJE-12-0967
Woodmansee, Whitney W. ; Zimmermann, Alan G. ; Child, Christopher J. ; Rong, Qi ; Erfurth, Eva Marie ; Beck-Peccoz, Paolo ; Blum, Werner F. ; Robison, Leslie L. / Incidence of second neoplasm in childhood cancer survivors treated with GH : An analysis of GeNeSIS and HypoCCS. In: European Journal of Endocrinology. 2013 ; Vol. 168, No. 4. pp. 565-573.
@article{5ff9bcf65057443a8f95518baec865a3,
title = "Incidence of second neoplasm in childhood cancer survivors treated with GH: An analysis of GeNeSIS and HypoCCS",
abstract = "Objective: Childhood cancer survivors are commonly treated with GH for GH deficiency that develops either as a result of primary malignancy or its treatment. One study - the Childhood Cancer Survivor Study (CCSS) - demonstrated increased risk of second neoplasm (SN) in GH-treated childhood cancer survivors compared with non-GH treated, after adjusting for key risk factors.We assessed the incidence of SN in GH-treated childhood cancer survivors in outpatient observational studies of GH replacement. Design: Retrospective analysis of two prospective cohort studies that collected data on safety of GH replacement as prescribed in clinical practice. Methods: Childhood cancer survivors enrolled in Eli Lilly and Company's pediatric (Genetics and Neuroendocrinology of Short Stature International Study (GeNeSIS)) and adult (Hypopituitary Control and Complications Study (HypoCCS)) observational studies of GH treatment were assessed for incidence of SN. Results: The percentage of childhood cancer survivors treated with GH who developed a SN was 3.8{\%} in pediatric GeNeSIS participants and 6.0{\%} in adult HypoCCS participants. The estimated cumulative incidence of SN at 5 years of follow-up in these studies was 6.2 and 4.8{\%} respectively. Conclusions: The incidence of SN in GeNeSIS and HypoCCS GH-treated participants is similar to the published literature and is thus consistent with increased risk of SN in childhood cancer survivors treated with GH. As follow-up times were relatively short (",
author = "Woodmansee, {Whitney W.} and Zimmermann, {Alan G.} and Child, {Christopher J.} and Qi Rong and Erfurth, {Eva Marie} and Paolo Beck-Peccoz and Blum, {Werner F.} and Robison, {Leslie L.}",
year = "2013",
month = "4",
doi = "10.1530/EJE-12-0967",
language = "English",
volume = "168",
pages = "565--573",
journal = "European Journal of Endocrinology",
issn = "0804-4643",
publisher = "BioScientifica Ltd.",
number = "4",

}

TY - JOUR

T1 - Incidence of second neoplasm in childhood cancer survivors treated with GH

T2 - An analysis of GeNeSIS and HypoCCS

AU - Woodmansee, Whitney W.

AU - Zimmermann, Alan G.

AU - Child, Christopher J.

AU - Rong, Qi

AU - Erfurth, Eva Marie

AU - Beck-Peccoz, Paolo

AU - Blum, Werner F.

AU - Robison, Leslie L.

PY - 2013/4

Y1 - 2013/4

N2 - Objective: Childhood cancer survivors are commonly treated with GH for GH deficiency that develops either as a result of primary malignancy or its treatment. One study - the Childhood Cancer Survivor Study (CCSS) - demonstrated increased risk of second neoplasm (SN) in GH-treated childhood cancer survivors compared with non-GH treated, after adjusting for key risk factors.We assessed the incidence of SN in GH-treated childhood cancer survivors in outpatient observational studies of GH replacement. Design: Retrospective analysis of two prospective cohort studies that collected data on safety of GH replacement as prescribed in clinical practice. Methods: Childhood cancer survivors enrolled in Eli Lilly and Company's pediatric (Genetics and Neuroendocrinology of Short Stature International Study (GeNeSIS)) and adult (Hypopituitary Control and Complications Study (HypoCCS)) observational studies of GH treatment were assessed for incidence of SN. Results: The percentage of childhood cancer survivors treated with GH who developed a SN was 3.8% in pediatric GeNeSIS participants and 6.0% in adult HypoCCS participants. The estimated cumulative incidence of SN at 5 years of follow-up in these studies was 6.2 and 4.8% respectively. Conclusions: The incidence of SN in GeNeSIS and HypoCCS GH-treated participants is similar to the published literature and is thus consistent with increased risk of SN in childhood cancer survivors treated with GH. As follow-up times were relatively short (

AB - Objective: Childhood cancer survivors are commonly treated with GH for GH deficiency that develops either as a result of primary malignancy or its treatment. One study - the Childhood Cancer Survivor Study (CCSS) - demonstrated increased risk of second neoplasm (SN) in GH-treated childhood cancer survivors compared with non-GH treated, after adjusting for key risk factors.We assessed the incidence of SN in GH-treated childhood cancer survivors in outpatient observational studies of GH replacement. Design: Retrospective analysis of two prospective cohort studies that collected data on safety of GH replacement as prescribed in clinical practice. Methods: Childhood cancer survivors enrolled in Eli Lilly and Company's pediatric (Genetics and Neuroendocrinology of Short Stature International Study (GeNeSIS)) and adult (Hypopituitary Control and Complications Study (HypoCCS)) observational studies of GH treatment were assessed for incidence of SN. Results: The percentage of childhood cancer survivors treated with GH who developed a SN was 3.8% in pediatric GeNeSIS participants and 6.0% in adult HypoCCS participants. The estimated cumulative incidence of SN at 5 years of follow-up in these studies was 6.2 and 4.8% respectively. Conclusions: The incidence of SN in GeNeSIS and HypoCCS GH-treated participants is similar to the published literature and is thus consistent with increased risk of SN in childhood cancer survivors treated with GH. As follow-up times were relatively short (

UR - http://www.scopus.com/inward/record.url?scp=84875127775&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875127775&partnerID=8YFLogxK

U2 - 10.1530/EJE-12-0967

DO - 10.1530/EJE-12-0967

M3 - Article

VL - 168

SP - 565

EP - 573

JO - European Journal of Endocrinology

JF - European Journal of Endocrinology

SN - 0804-4643

IS - 4

ER -